Lineage Cell Therapeutics, Inc. (LCTX) is a publicly traded Healthcare sector company. As of May 20, 2026, LCTX trades at $1.26 with a market cap of $309.13M and a P/E ratio of -4.38. LCTX moved +3.33% today. Year to date, LCTX is -26.83%; over the trailing twelve months it is +141.25%. Its 52-week range spans $0.37 to $2.09. Analyst consensus is strong buy with an average price target of $6.25. Rallies surfaces LCTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Lineage Cell Therapeutics, Inc. (LCTX) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. LCTX moved +3.33% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $1.26 |
| Market Cap | $309.13M |
| P/E Ratio | -4.38 |
| EPS | $-0.28 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.09 |
| 52-Week Low | $0.37 |
| Volume | 328.72K |
| Avg Volume | 0 |
| Revenue (TTM) | $14.78M |
| Net Income | $-64.01M |
| Gross Margin | 0.00% |
4 analysts cover LCTX: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.25.